Xtant Medical Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Oct 29, 2020 and accepted by EDGAR at Oct 29, 2020, 07:30 ET.
Management's discussion and analysis
As filed, 27,320 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
This Management’s Discussion and Analysis provides material historical and prospective disclosures intended to enable investors and other users to assess our financial condition and results of operations. The following discussion should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and accompanying notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed above in “Cautionary Statement Regarding Forward-Looking Statements” and elsewhere in this Form 10-Q.
Business Overview
We develop, manufacture, and market regenerative medicine products and medical devices for domestic and international markets. Our products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants, and instrumentation for the treatment of spinal disease. We promote our products in the United States largely through independent distributors and stocking agents, augmented by direct employees.
Recent Debt Restructuring
On August 7, 2020, we entered into a Restructuring and Exchange Agreement with OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP, pursuant to which the parties thereto agreed, subject to the terms and conditions set forth therein, to take certain actions as set forth therein and as described below in furtherance of a restructuring of the Company’s outstanding indebtedness under Second Amended and Restated Credit Agreement.
The Restructuring Transactions include, among others:
- an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock, par value $0.000001 per share, of the Company from 75 million to 300 million, which became effective on October 1, 2020;
- the exchange by the Company of shares of our common stock for approximately $40.8 million of the aggregate outstanding principal amount of the Loans (as defined in the Second Amended and Restated Credit Agreement) outstanding under the Second Amended and Restated Credit Agreement, as well as, without duplication, approximately $21.1 million of the outstanding amount of PIK Interest (as defined in the Second Amended and Restated Credit Agreement), plus all other accrued and unpaid interest on the Exchanging Loans outstanding as of the closing date, at an exchange price of $1.07 per share, representing the average closing price of the common stock over the 10 trading days immediately prior to the parties entering into the Restructuring Agreement, and resulting in the issuance of approximately 57.8 million shares of common stock, which occurred on October 1, 2020;
- the execution of an amendment to the Second Amended and Restated Credit Agreement by the parties thereto to change certain provisions therein which occurred on October 1, 2020 and is described in more detail below; and
- the launch by the Company of a rights offering to allow stockholders of the Company to purchase up to an aggregate of $15 million of common stock at the same price per share as the $1.07 per share exchange price used to exchange the Exchanging Loans into common stock as part of the Share Issuance, the details of which the Company announced publicly on October 22, 2020 and are described in more detail below.
17
As a result of the completion of these Restructuring Transactions, Royalty Opportunities and ROS own, in the aggregate, approximately 94.5% of the outstanding common stock and all other existing stockholders of the Company own approximately 5.5% of the outstanding common stock. Following completion of these Restructuring Transactions the remaining principal balance of our outstanding debt totals $15.6 million.
Also on October 1, 2020, in connection with and as a condition to the Closing of the Restructuring Transactions, the Company entered into a Registration Rights Agreement with the Lenders, which requires the Company to, among other things, file with the SEC a shelf registration statement covering the resale, from time to time, of the common stock issuable upon exchange of the Exchanging Loans and the Prepayment Fee Shares no later than the 90th day after the closing date and use its best efforts to cause the shelf registration statement to become effective under the Securities Act, no later than the 180th day after the closing date.
As a result of the completion of the debt restructuring, on October 5, 2020 we received notification from NYSE Regulation that the Company had regained compliance with all of the continued listing standards of the NYSE American, including in particular the requirement under NYSE American Company Guide Section 1003(a)(iii) that requires a listed issuer to maintain stockholders’ equity of at least $6 million if it has reported losses from continuing operations, and/or net losses, in its five most recent fiscal years.
Impact of the COVID-19 Pandemic
Since March 2020, the COVID-19 pandemic has caused business closures, severe travel restrictions and implementation of social distancing measures. At the onset of the COVID-19 pandemic, hospitals and other medical facilities cancelled or deferred elective procedures, diverted resources to patients suffering from infections and limited access for non-patients, including our direct and indirect sales representatives. Because of the COVID-19 pandemic, surgeons and their patients have been, and may continue to be, required, or are choosing, to defer procedures in which our products otherwise would be used, and many facilities that specialize in the procedures in which our products otherwise would be used have experienced temporary closures or reduced operating hours. These circumstances have negatively impacted, and may continue to negatively impact, the ability of our employees, independent sales representatives and distributors to effectively market and sell our products, which has had and will likely continue to have a material adverse effect on our revenues. In addition, even after the easing of such restrictions such that governmental orders no longer prohibit or recommend against performing such procedures, patients may continue to defer such procedures out of concern of being exposed to coronavirus or for other reasons.
The COVID-19 pandemic has also caused adverse effects on general commercial activity and the global economy, which has led to an economic recession and could cause other unpredictable events, any of which could adversely affect our business, operating results or financial condition. The adverse effect of the pandemic on the broader economy also will likely negatively affect demand for procedures using our products, both in the near- and long-term, and could cause one or more of our distributors, independent sales representatives, customers, contract manufacturers and suppliers to experience financial distress, cancel, postpone or delay orders, be unable to perform under a contract, file for bankruptcy protection, go out of business, or suffer disruptions in their business. This could impact our ability to manufacture and provide products and otherwise operate our business, as well as increase our costs and expenses.
The anticipated decline in our revenues and adverse impact on our other operating results could impact our debt covenants under our credit facility and our ability to access funding thereunder. We may need to borrow funds from alternative sources, such as other lenders and institutions or government agencies. There can be no guarantee that such borrowing will be available or available on favorable terms or without restrictions that may otherwise impair our operating flexibility. The COVID-19 pandemic has also led to and could continue to lead to severe disruption and volatility in the global capital markets, which could increase our cost of future capital and adversely affect our ability to access the capital markets in the future.
In response to the COVID-19 pandemic, during the second quarter of 2020, we implemented a series of cost-savings actions intended to preserve capital to support our operations. These temporary cost-saving actions included:
- termination or furlough of 42% of our workforce;
- suspension in hiring most open positions;
- elimination of planned merit increases;
- institution of a temporary 20% base salary or wage reduction for all executive officers and employees;
- 20% reduction in non-employee director retainers for second quarter of 2020;
- suspension of future 401(k) plan matching contributions by the Company; and
- reduction in sales and marketing expenses and other discretionary spending.
Effective July 1, 2020, we reinstituted the full base salaries and wages of all our employees and restored future 401(k) plan matching contributions.
COVID-19 has resulted and will likely continue to result in a material adverse effect on our business, operating results, financial condition, prospects and the trading price of our common stock in the near-term and beyond 2020. The full extent to which the COVID-19 pandemic will impact our business will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact.
Results of Operations
Comparison of Three and Nine Months Ended September 30, 2020 and September 30, 2019
Revenue
Total revenue for the three and nine months ended September 30, 2020 was $14.0 million and $39.3 million, respectively, which represents a decrease of 10.8% and 17.6%, respectively, compared to $15.7 million and $47.7 million for the three and nine months ended September 30, 2019, respectively. The decrease in revenue is largely attributed to the impact of COVID-19 and the sudden drop in elective procedures beginning in early March 2020, which has recovered, to some extent, as evident by third quarter 2020 revenue representing close to 90% of third quarter 2019 revenue.
Cost of Sales and Gross Profit
Cost of sales consists primarily of manufacturing and product purchase costs as well as depreciation of surgical trays. Cost of sales also includes reserves for estimated excess inventory, inventory on consignment that may be missing and not returned, and reserves for estimated missing and damaged consigned surgical instruments. Cost of sales decreased by 10.2%, or $0.5 million, to $4.8 million for the three months ended September 30, 2020 from $5.3 million for the three months ended September 30, 2019. Cost of sales decreased by 16.3%, or $2.7 million, to $13.9 million for the nine months ended September 30, 2020 from $16.6 million for the nine months ended September 30, 2019. The reduction in cost of sales is primarily due to lower revenue during the three and nine months ended September 30, 2020 versus the comparable periods in 2019, as mentioned above.
Gross profit as a percentage of sales decreased to 66.0% for the three months ended September 30, 2020 compared to 66.2% for the same period in 2019. Gross profit as a percentage of sales decreased to 64.6% for the nine months ended September 30, 2020 compared to 65.2% for the same period in 2019. The reductions during the three and nine months ended September 30, 2020 compared to the same period in the prior year are primarily attributable to diminished economies of scale partially offset by reduced depreciation expense.
General and Administrative
General and administrative expenses consist principally of personnel costs for corporate employees, cash-based and stock-based compensation related costs, and corporate expenses for legal, accounting, professional fees, and occupancy costs. General and administrative expenses decreased 28.0%, or $1.2 million, to $3.0 million for the three months ended September 30, 2020, compared to $4.2 million for the same period in 2019. General and administrative expenses decreased 20.0%, or $2.6 million, to $10.3 million for the nine months ended September 30, 2020, compared to $12.9 million for the same period in 2019. The decrease for the three-month comparison is primarily attributable to lower legal and consulting fees of $0.6 million, reduced executive recruiting fees of $0.2 million, and reduced salaries and wages of $0.2 million during the three months ended September 30, 2020. The decrease for the nine-month comparison is primarily attributable to lower legal and consulting fees of $1.7 million, reduced legal settlement expenses of $0.8 million, reduced salaries and wages of $0.6 million, reduced executive recruiting fees of $0.5 million, and reduced license fees of $0.3 million during the nine months ended September 30, 2020. This decrease was offset partially by severance expense of $0.7 million and additional stock-based compensation expense of $0.5 million during the nine months ended September 30, 2020. The reduced salaries and wages were due to the reduction in headcount and the temporary 20% salary and wage decreases implemented during the second quarter of 2020 in response to the COVID-19 pandemic.
Sales and Marketing
Sales and marketing expenses consist primarily of sales commissions, personnel costs for sales and marketing employees, costs for trade shows, sales conventions and meetings, travel expenses, advertising, and other sales and marketing related costs. Sales and marketing expenses decreased 21.2%, or $1.4 million, to $5.3 million for the three months ended September 30, 2020, compared to $6.7 million for the same period of 2019. Sales and marketing expenses decreased 20.1%, or $3.9 million, to $15.6 million for the nine months ended September 30, 2020, compared to $19.5 million for the same period of 2019. The decrease for the three-month comparison is primarily due to the reduction in sales commissions of $0.5 million due to lower revenues versus the comparable period in 2019 and reduced salaries and wages of $0.5 million due to the reduction in headcount implemented during the second quarter of 2020 in response to the COVID-19 pandemic. The decrease for the nine-month comparison is primarily due to the reduction in sales commissions of $2.4 million due to lower revenues versus the comparable period in 2019, reduced salaries and wages of $1.0 million and lower travel expenses of $0.3 million compared to the comparable period in 2019.
Research and Development
Research and development expenses consist primarily of internal costs for the development of new technologies and processes. Research and development expenses of $0.2 million for the three months ended September 30, 2020 were comparable to the $0.2 million recorded during the three months ended September 30, 2019. Research and development expenses decreased 21.6%, or $0.1 million, to $0.5 million for the nine months ended September 30, 2020, compared to $0.7 million for the nine months ended September 30, 2019. The reduction in research and development expenses is primarily due to reduced salaries and wages during the nine months ended September 30, 2020 compared to the prior year period.
Interest Expense
Interest expense is related to interest incurred from our debt instruments. Interest expense was $2.1 million for the three months ended September 30, 2020 compared to $1.2 million for the three months ended September 30, 2019. Interest expense was $5.3 million for the nine months ended September 30, 2020 and $4.5 million for the nine months ended September 30, 2019. The increase in interest expense during the three and nine months ended September 30, 2020 versus the comparable periods in 2019 resulted from additional interest associated with the First Amendment.
Liquidity and Capital Resources
Working Capital
Since our inception, we have financed our operations through operating cash flows, the private placement of equity securities and convertible debt, an equity credit facility, a debt facility, a common stock rights offering, and other debt transactions.
| September 30, 2020 | December 31, 2019 | |
|---|---|---|
| Cash and cash equivalents | $2,741 | $5,237 |
| Accounts receivable, net | 7,317 | 10,124 |
| Inventories | 20,671 | 16,101 |
| Total current assets | 32,385 | 32,246 |
| Accounts payable | 2,814 | 2,188 |
| Accrued liabilities | 6,043 | 6,632 |
| Total current liabilities | 9,331 | 9,390 |
| Total working capital | 23,054 | 22,856 |
| Long-term debt, plus premium and less issuance costs | 79,627 | 76,244 |
Cash Flows
Net cash used in operating activities for the first nine months of 2020 was $1.6 million attributed to the increase in inventories of $5.0 million and increase in prepaid expenses of $0.9 million, offset partially by the decrease in accounts receivable of $2.5 million and increase in accounts payable of $0.6 million. For the comparable period of 2019, net cash used in operating activities was $0.3 million.
Net cash used in investing activities for the first nine months of 2020 and 2019 was $0.8 million and $0.2 million, respectively, primarily representing purchases of property and equipment.
Net cash used in financing activities was $0.1 million and $0.5 million for the first nine months of 2020 and 2019, respectively, primarily representing payments for financing leases.
Credit Facility
On March 29, 2019, we entered into the Second Amended and Restated Credit Agreement with the Lenders. The Second Amended and Restated Credit Agreement amended the Prior Credit Agreement to provide that we may request term loans from the Lenders in their sole discretion in an amount equal to the remaining availability for additional delayed draw loans, which was approximately $2.2 million as of the date of the Second Amended and Restated Credit Agreement, and request additional term loans from the Lenders in their sole discretion in an aggregate amount of up to $10.0 million, the amount of each loan draw to be also subject to our production of a thirteen-week cash flow forecast that is approved by the Lenders and which shows a projected cash balance for the following two-week period of less than $1.5 million, as well as the satisfaction (or waiver in writing by each Lender) of conditions precedent, including closing certificate, delivery of a budget, and other satisfactory documents. In addition, the Second Amended and Restated Credit Agreement provides that (i) no interest will accrue on the loans thereunder from and after January 1, 2019 until March 31, 2020; (ii) beginning April 1, 2020, through the maturity date of the Second Amended and Restated Credit Agreement, interest payable in cash will accrue on the loans thereunder at a rate per annum equal to the sum of (a) 10.00% plus (b) the higher of (x) the LIBO Rate (as such term is defined in the Second Amended and Restated Credit Agreement) and (y) 2.3125%; (iii) the maturity date of the loans thereunder is March 31, 2021; (iv) the Consolidated Senior Leverage Ratio and Consolidated EBITDA (as such terms were defined in the Prior Credit Agreement) financial covenants were deleted and a new Revenue Base (as such term is defined in the Second Amended and Restated Credit Agreement) financial covenant was added; and (v) the key person event default provision was revised to refer specifically to certain then recently-hired executive officers of the Company.
On May 6, 2020, we entered into a First Amendment to the Second Amended and Restated Credit Agreement with the Lenders, which amended the Second Amended and Restated Credit Agreement. Under the terms of the First Amendment, the Second Amended and Restated Credit Agreement was amended to provide that:
- No interest will accrue on the outstanding loans under the Second Amended and Restated Credit Agreement from and after March 31, 2020 until September 30, 2020;
- Beginning October 1, 2020 through the maturity date of the Second Amended and Restated Credit Agreement, interest payable in cash will accrue on the loans under the Second Amended and Restated Credit Agreement at a rate per annum equal to the sum of (i) 10.00% plus (ii) the higher of (x) the LIBO Rate (as such term is defined in the Second Amended and Restated Credit Agreement) and (y) 2.3125%;
- The maturity date of the loans thereunder is December 31, 2021;
- The Revenue Base financial covenant was revised through December 31, 2021; and
- The key person event default provision was revised to refer specifically to Sean Browne in lieu of a former executive.
On August 7, 2020, we entered into the Restructuring Agreement with the Lenders, pursuant to which the parties thereto agreed, subject to the terms and conditions set forth therein, to take certain actions as set forth therein in furtherance of a restructuring of the Company’s outstanding indebtedness under Second Amended and Restated Credit Agreement. The Restructuring Transactions and other details related thereto are described above under “Recent Debt Restructuring.” As part of the Restructuring Transactions, we entered into a Second Amendment to the Second Amended and Restated Credit Agreement with the Lenders, which amended the Second Amended and Restated Credit Agreement as follows:
- extinguished loans in an aggregate principal amount equal to the Exchanging Loans outstanding thereunder on the Closing Date, immediately prior to the Closing, together with all accrued and unpaid interest thereon;
- added loans in an aggregate principal amount equal to a portion of the prepayment fee payable thereunder in respect of the Exchanging Loans and exchanged the remaining portion of the prepayment fee for an additional 0.9 million shares of common stock;
- removed the availability of the Additional Delayed Draw Loans and reduced the Additional Second Delayed Draw Commitment Amount (as such terms are defined in the Second Amended and Restated Credit Agreement) to $5.0 million;
- provided that beginning on October 1, 2020 through the maturity date of the Second Amended and Restated Credit Agreement, interest payable in cash will accrue on the loans thereunder at a rate per annum equal to the sum of (i) 7.00% plus (ii) the higher of (x) the LIBO Rate (as such term is defined in the Second Amended and Restated Credit Agreement) and (y) 1.00%; and
- eliminated the Revenue Base financial covenant.
As of September 30, 2020, we were in compliance with all covenants under the Second Amended and Restated Credit Agreement, as amended by the First Amendment.
Cash Requirements
As of September 30, 2020, our cash and cash equivalents were $2.7 million. We believe that our cash and cash equivalents, together with the current $5.0 million availability under our credit facility which is subject to the sole discretion of the Lenders, will be sufficient to meet our anticipated cash requirements for at least the next 12 months. However, we may require additional financing to fund our future operations and business strategy. Accordingly, there is no assurance that we will not need or seek additional financing prior to such time, especially in light of the December 31, 2021 maturity date under our credit facility. We may elect to raise additional financing even before we need them if market conditions for raising additional capital are favorable. We may seek to raise additional financing through various sources, such as debt refinancings, equity and debt financings, additional debt restructurings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to refinance our existing indebtedness or secure additional sources of funds to support our operations, or if such financing is available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if economic and market conditions deteriorate.
To the extent that we raise additional capital through the sale of equity or convertible debt securities or the restructuring or refinancing of our debt, the interests of our current stockholders may be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our current stockholders. If we issue preferred stock, it could affect the rights of our stockholders or reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. Prior to raising additional equity or debt financing, we must obtain the consent of the Lenders, and no assurance can be provided that the Lenders would provide such consent, which could limit our ability to raise additional financing.
Off Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity or capital expenditures, or capital resources that are material to an investor in our common stock.
Critical Accounting Estimates
Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and any such differences may be material.
There have been no changes in our critical accounting estimates for the three and nine months ended September 30, 2020 as compared to the critical accounting estimates described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 other than for adoption of ASU 2016-13 as described in Note 1 and Note 3 to our condensed consolidated financial statements.
Controls and procedures
As filed, 1,445 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of September 30, 2020. Based upon that evaluation, our principal executive officer and principal financial officer concluded that as of September 30, 2020, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
There were no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended September 30, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 4,393 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Although Item 1A is inapplicable to Xtant as a smaller reporting company, we hereby disclose the following additional risk:
The Company’s business, operating results and financial condition have been and will likely continue to be materially adversely affected by the global novel strain of coronavirus (COVID-19) pandemic.
Since March 2020, the COVID-19 pandemic has caused business closures, severe travel restrictions and implementation of social distancing measures. At the onset of the COVID-19 pandemic, hospitals and other medical facilities cancelled or deferred elective procedures, diverted resources to patients suffering from infections and limited access for non-patients, including our direct and indirect sales representatives. Because of the COVID-19 pandemic, surgeons and their patients have been, and may continue to be, required, or are choosing, to defer procedures in which our products otherwise would be used, and many facilities that specialize in the procedures in which our products otherwise would be used have experienced temporary closures or reduced operating hours. These circumstances have negatively impacted, and may continue to negatively impact, the ability of our employees, independent sales representatives and distributors to effectively market and sell our products, which has had and will likely continue to have a material adverse effect on our revenues. In addition, even after the easing of such restrictions such that governmental orders no longer prohibit or recommend against performing such procedures, patients may continue to defer such procedures out of concern of being exposed to coronavirus or for other reasons.
The COVID-19 pandemic has also caused adverse effects on general commercial activity and the global economy, which has led to an economic slowdown and recession and could cause other unpredictable events, any of which could adversely affect our business, operating results or financial condition. The adverse effect of the pandemic on the broader economy also will likely negatively affect demand for procedures using our products, both in the near- and long-term. In addition, as a result of this negative effect on our economy, one or more of our distributors, independent sales representatives, customers, contract manufacturers and suppliers may experience financial distress, cancel, postpone or delay orders, be unable to perform under a contract, file for bankruptcy protection, go out of business, or suffer disruptions in their business or we may need to offer special payment terms or relief to our distributors, independent sales representatives and customers. Accordingly, we believe we will be exposed to heightened credit risk as a result of the pandemic. This could adversely impact our ability to manufacture and provide products and otherwise operate our business, as well as increase our costs and expenses.
The anticipated decline in our revenues and adverse impact on our other operating results could impact our debt covenants under our credit facility and our ability to access funding thereunder. We may need to borrow funds from alternative sources, such as other lenders and institutions or government agencies. There can be no guarantee that such borrowing will be available or available on favorable terms or without restrictions that may otherwise impair our operating flexibility. The COVID-19 pandemic has also led to and could continue to lead to severe disruption and volatility in the global capital markets, which could increase our cost of future capital and adversely affect our ability to access the capital markets in the future.
The foregoing and other continued disruptions to our business as a result of COVID-19 have resulted and could continue to result in a material adverse effect on our business, operating results, financial condition, prospects and the trading price of our common stock in the near-term and beyond 2020. The full extent to which the COVID-19 pandemic will impact our business will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact. The COVID-19 pandemic also heightens the risks in certain of the other risk factors described in our Annual Report Form 10-K for the year ended December 31, 2019.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $14.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $39.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-07-01 to 2020-09-30 | $4.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2020-01-01 to 2020-09-30 | $13.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2020-07-01 to 2020-09-30 | $9.2m | us-gaap:GrossProfit |
| Gross profit | 9 months2020-01-01 to 2020-09-30 | $25.4m | us-gaap:GrossProfit |
| Research and development | 3 months2020-07-01 to 2020-09-30 | $176.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $529.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | $760.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | −$991.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-07-01 to 2020-09-30 | $2.1m | us-gaap:InterestExpense |
| Interest expense | 9 months2020-01-01 to 2020-09-30 | $5.3m | us-gaap:InterestExpense |
| Income tax | 3 months2020-07-01 to 2020-09-30 | $23.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $68.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | −$1.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | −$6.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | −$0.10 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | −$0.48 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-07-01 to 2020-09-30 | −$0.10 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-01-01 to 2020-09-30 | −$0.48 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-07-01 to 2020-09-30 | 13,231,823 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-01-01 to 2020-09-30 | 13,210,386 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | −$1.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $907.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-09-30 | $2.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $32.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $42.4m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $9.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $90.4m | us-gaap:Liabilities |
| Long-term debt | At period end2020-09-30 | $79.6m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2020-09-30 | −$48.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-20-020089. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.